Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Background: Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes. Methods: Participants ( n =7020) were randomized (1:1:1) to empagliflozin 10 mg/d, empagliflozin 25 mg/d, or placebo added to standard of care. We calculated eGFR slopes using random-intercept/random-coefficient models for prespecified study periods: treatment initiation (baseline to week 4), chronic maintenance treatment (week 4 to last value on treatment), and post-treatment (last value on treatment to follow-up). Results: Compared with placebo, empagliflozin was associated with uniform shifts in individual eGFR slopes across all periods. On treatment initiation, adjusted mean slope (eGFR change per week, ml/min per 1.73 m 2 ) decreased with empagliflozin (−0.77; 95% confidence interval, −0.83 to −0.71; placebo: 0.01; 95% confidence interval, −0.08 to 0.10; P <0.001). However, annual mean slope (ml/min per 1.73 m 2 per year) did not decline with empagliflozin during chronic treatment (empagliflozin: 0.23; 95% confidence interval, 0.05 to 0.40; placebo: −1.46; 95% confidence interval, −1.74 to −1.17; P <0.001). After drug cessation, the adjusted mean eGFR slope (ml/min per 1.73 m 2 per week) increased and mean eGFR returned toward baseline level only in the empagliflozin group (0.56; 95% confidence interval, 0.49 to 0.62; placebo −0.02; 95% confidence interval, −0.12 to 0.08; P <0.001). Results were consistent across patient subgroups at higher CKD risk. Conclusions: The hemodynamic effects of empagliflozin, associated with reduction in intraglomerular pressure, may contribute to long-term preservation of kidney function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The cardiovascular and kidney bene fi ts appear independent of glucose-lowering, suggesting other mechanisms for organ protection, such as reduction in intraglomerular pressure and single-nephron hyper fi ltration leading to preservation of kidney function. 105”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This incident or worsening nephropathy outcome was lower in the empagli fl ozin group -12.7% versus 18.8% -with a HR of 0.61 (95% CI: 0.53 -0.70).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2i conferred less annual eGFR decline and a reduction in albuminuria or decreased progression to severely increased albuminuria.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredIn the citing paper
“Clinically this is manifested by an acute drop in the estimated glomerular filtration rate (eGFR) of approximately 4 to 6 mL/min/1.73m 2 in the first weeks after initiation of SGLT2 inhibition.”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as Wanner et al., 2018
In the citing paper
“Importantly, this drop in eGFR is associated with a preservation of long-term kidney function during prolonged treatment and is reversible soon after discontinuation of SGLT2 inhibitors (Wanner et al., 2018).”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as Wanner et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationDe Rosa, S., Samoni, S., Villa, G., & Ronco, C. (2017) · Blood Purification · doi:10.1159/000452650 · Cited by 5,007
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Self-citationGlomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
Self-citationLevey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Self-citation
Cited by
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationNeuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893
Self-citationMechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects
Griffin, M., Rao, V. S., Ivey-Miranda, J., Fleming, J., Mahoney, D., Maulion, C., Suda, N., Siwakoti, K., Ahmad, T., Jacoby, D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045691 · Cited by 414
Self-citationRenin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease
Bhandari, S., Mehta, S., Khwaja, A., Cleland, J. G. F., Ives, N., Brettell, E., Chadburn, M., & Cockwell, P. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210639 · Cited by 328
Yurista, S. R., Silljé, H. H. W., Oberdorf-Maass, S. U., Schouten, E.-M., Pavez Giani, M. G., Hillebrands, J.-L., van Goor, H., van Veldhuisen, D. J., de Boer, R. A., & Westenbrink, B. D. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1473 · Cited by 321
Rosano, G. M. C., Moura, B., Metra, M., Böhm, M., Bauersachs, J., Ben Gal, T., Adamopoulos, S., Abdelhamid, M., Bistola, V., Čelutkienė, J., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2206 · Cited by 269
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 266
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Kraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.031 · Cited by 219
Self-citationLu, Q., Yang, L., Xiao, J.-J., Liu, Q., Ni, L., Hu, J.-W., Yu, H., Wu, X., & Zhang, B.-F. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.088 · Cited by 212
Heerspink, H. J. L., Jongs, N., Chertow, G. M., Langkilde, A. M., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., Stefansson, B. V., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00242-4 · Cited by 206
Self-citationEffects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
Boorsma, E. M., Beusekamp, J. C., ter Maaten, J. M., Figarska, S. M., Danser, A. H. J., van Veldhuisen, D. J., van der Meer, P., Heerspink, H. J. L., Damman, K., & Voors, A. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2066 · Cited by 178
Self-citationMc Causland, F. R., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P., de Boer, R. A., Docherty, K., Fang, J., Hernandez, A. F., Inzucchi, S. E., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4210 · Cited by 131
Self-citationA kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Sen, T., & Heerspink, H. J. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.016 · Cited by 161
Self-citationAdamson, C., Docherty, K. F., Heerspink, H. J. L., de Boer, R. A., Damman, K., Inzucchi, S. E., Køber, L., Kosiborod, M., Martínez, F. A., Petrie, M. C., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058910 · Cited by 155
Self-citationJudge, P., Staplin, N., Mayne, K., Wanner, C., Green, J., Hauske, S. J., Emberson, J., Preiss, D., Ng, S., Roddick, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00322-4 · Cited by 155
“19 ,19–22 The presented results might also indicate other common pathways driven by pathophysiology in the kidney tubules.”
Self-citationNeuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Li, Q., Jardine, M., Oh, R., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019010064 · Cited by 131
Self-citationHeerspink, H. J. L., Sjöström, C. D., Jongs, N., Chertow, G. M., Kosiborod, M., Hou, F. F., McMurray, J. J. V., Rossing, P., Correa-Rotter, R., Kurlyandskaya, R., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab094 · Cited by 121
Self-citationManagement of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 125
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.036 · Cited by 121
Jongs, N., Chertow, G. M., Greene, T., McMurray, J. J. V., Langkilde, A. M., Correa‐Rotter, R., Kashihara, N., Rossing, P. R., Sjöström, C. D., Stefánsson, B. V., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2022030306 · Cited by 114
Self-citationNew pharmacological strategies for protecting kidney function in type 2 diabetes
Muskiet, M. H. A., Wheeler, D. C., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30263-8 · Cited by 107
Self-citationKanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 111
Levin, A., Perkovic, V., Wheeler, D. C., Hantel, S., George, J. T., von Eynatten, M., Koitka‐Weber, A., Wanner, C., & on behalf of the EMPA-REG OUTCOME Investigators (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14901219 · Cited by 99
“0) Background medications ACE inhibitors/ARBs 846 (77) 1754 (79) 556 (82) 1119 (83) 305 (85) 585 (82) 147 (79) 299 (83) Diuretics 405 (37) 841 (38) 295 (44) 605 (45) 172 (48) 360 (51) 110 (59) 216 (60) History of heart failure 95 (9) 181 (8) 77 (11) 146 (11) 48 (13) 84 (12) 23 (12) 50 (14) Smoking status Never smoked…”
MethodResultInfluentialSelf-citationEffects of Selonsertib in Patients with Diabetic Kidney Disease
Chertow, G. M., Pérgola, P. E., Fang, C., Kirby, B. J., Sundy, J. S., Patel, U. D., & for the GS-US-223-1015 Investigators (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018121231 · Cited by 97
Empagliflozin Suppresses Inflammation and Protects Against Acute Septic Renal Injury
Maayah, Z. H., Ferdaoussi, M., Takahara, S., Soni, S., & Dyck, J. R. B. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00732-4 · Cited by 93
on behalf of the ADVANCE Collaborative Group, Oshima, M., Jun, M., Ohkuma, T., Toyama, T., Wada, T., Cooper, M. E., Hadjadj, S., Hamet, P., Harrap, S. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4948-4 · Cited by 87
Fitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13615 · Cited by 85
“followed by stabilization during prolonged treatment, in contrast to a gradual decline in eGFR in the placebo group.(4) Empagliflozin also led to significant reductions in the urine al-”
Self-citationMosenzon, O., Raz, I., Wiviott, S. D., Schechter, M., Goodrich, E. L., Yanuv, I., Rozenberg, A., Murphy, S. A., Zelniker, T. A., Langkilde, A. M., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0382 · Cited by 83
Self-citationSGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
Davidson, J. A. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1601404 · Cited by 82
Rampersad, C., Kraut, E., Whitlock, R. H., Komenda, P. V. J., Woo, V. C., Rigatto, C., & Tangri, N. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.03.019 · Cited by 72
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Blais, J., Li, Q., Jardine, M. J., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.06.018 · Cited by 70
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 69
Blood Flow Restriction Training Blunts Chronic Kidney Disease Progression in Humans
Corrêa, H. D. L., Neves, R. V. P., Deus, L. A., Souza, M. K., Haro, A. S., Costa, F., Silva, V. L., Santos, C. A. R., Moraes, M. R., Simões, H. G., et al. (2020) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002465 · Cited by 60
Kim, N. H., & Kim, N. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0209 · Cited by 59
“First, the renal benefit of SGLT2 inhibitors is consistent regardless of CKD stage and albuminuria [21,22,29,30,32,33].”
BackgroundAntioxidant Roles of SGLT2 Inhibitors in the Kidney
Llorens-Cebrià, C., den Bosch, M. M. V., Vergara, A., Jacobs-Cachá, C., & Soler, M. J. (2022) · Biomolecules · doi:10.3390/biom12010143 · Cited by 57
Butler, J., Zannad, F., Fitchett, D., Zinman, B., Koitka-Weber, A., von Eynatten, M., Zwiener, I., George, J., Brueckmann, M., Cheung, A. K., et al. (2019) · Circulation: Heart Failure · doi:10.1161/circheartfailure.118.005875 · Cited by 49
Self-citationTherapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease
Shaffner, J., Chen, B., Malhotra, D. K., Dworkin, L. D., & Gong, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.749010 · Cited by 52
Causland, F. R. M., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., Vardeny, O., Fang, J. C.-T., de Boer, R. A., Docherty, K. F., Hernandez, A. F., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.4664 · Cited by 51
Self-citationErtugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial
Cherney, D. Z. I., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Frederich, R. C., Maldonado, M., Liu, C., Liu, J., Pong, A., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01130121 · Cited by 51
Gong, Q., Zhang, R., Wei, F., Fang, J., Zhang, J., Sun, J., Sun, Q., & Wang, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113222 · Cited by 49
SGLT2 inhibition to address the unmet needs in diabetic nephropathy
Barutta, F., Bernardi, S., Gargiulo, G., Durazzo, M., & Gruden, G. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3171 · Cited by 47
Small Fiber Neuropathy in Diabetes Polyneuropathy: Is It Time to Change?
Sharma, S., Vas, P. R. J., & Rayman, G. A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821996434 · Cited by 44
Rastogi, A., & Januzzi, J. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082824 · Cited by 42
“SGLT2is confer renop otective effects irrespective of baseline eGFR and CKD stag [30,68], and long-term SGLT2i therapy preserves kidney fu ction in patients with and without T2D [60,69].”
BackgroundEstablished and emerging treatments for diabetes-associated lower urinary tract dysfunction
Erdoğan, B. R., Liu, G., Arioglu‐Inan, E., & Michel, M. C. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02249-9 · Cited by 42
Invited review. Series: Implications of the recent CVOTs in type 2 diabetes
Dardano, A., Miccoli, R., Bianchi, C., Daniele, G., & Prato, S. D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108112 · Cited by 40
Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.1487 · Cited by 39
Self-citationAtiquzzaman, M., Thompson, J. R., Shao, S., Djurdjev, O., Bevilacqua, M. U., Wong, M., Levin, A., & Birks, P. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad121 · Cited by 39
Nonproteinuric progressive diabetic kidney disease
Zoccali, C., & Mallamaci, F. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000489 · Cited by 39
Barratt, J., Rovin, B. H., Diva, U., Mercer, A., & Komers, R. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.08.007 · Cited by 38
“, rate of decline of kidney function measured after excluding an initial period to account for the acute hemodynamic effect of the drug to the end of the treatment period) reflected well the beneficial therapeutic effect of empagliflozin as compared with placebo.(4) Moreover, after drug withdrawal, eGFR increased sign…”
ResultTakeuchi, M., Ogura, M., Minoura, T., Inagaki, N., & Kawakami, K. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.12.004 · Cited by 38
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
Neuen, B. L., Tighiouart, H., Heerspink, H. J. L., Vonesh, E. F., Chaudhari, J., Miao, S., Chan, T. M., Fervenza, F. C., Floege, J., Goicoechea, M., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070948 · Cited by 37
Self-citationExpectations in children with glomerular diseases from SGLT2 inhibitors
Cirillo, L., Ravaglia, F., Errichiello, C., Anders, H., Romagnani, P., & Becherucci, F. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05504-6 · Cited by 37
“The shift in kidney metabolism from fat and glucose oxidation toward energy-efficient ketogenesis is thought to improve cellular efficiency and function [56].”
BackgroundInfluentialType 2 diabetes and the kidney: Insights from cardiovascular outcome trials
Giugliano, D., Nicola, L. D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13743 · Cited by 37
Major adverse renal events (MARE): a proposal to unify renal endpoints
Prischl, F. C., Rossing, P. R., Bakris, G. L., Mayer, G. J., & Wanner, C. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz212 · Cited by 37
Self-citationWanner, C., Inzucchi, S. E., Zinman, B., Koitka‐Weber, A., Mattheus, M., George, J. T., von Eynatten, M., Hauske, S. J., & EMPA‐REG OUTCOME Investigators (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14158 · Cited by 37
“the chronic maintenance treatment period) and results are expressed as annual changes in eGFR in accordance with previously published prespecified analysis.(21) Safety has already been reported in the overall population,(13,14) and was assessed in the current analysis based on AEs reported in relevant subgroups.”
MethodResultInfluentialSelf-citationHbA1c‐dependent projection of long‐term renal outcomes
Arnold, F., Kappes, J., Rottmann, F. A., Westermann, L., & Welte, T. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13736 · Cited by 35
“The relative annual eGFR decline was similar to previously reported cohorts of people with diabetes and/or CKD [36].”
ResultScheen, A. J. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1733967 · Cited by 35
“After drug cessation, the adjusted mean eGFR slope increased and mean eGFR returned toward baseline level only in the empagliflozin group [48].”
BackgroundProvenzano, M., Pelle, M. C., Zaffina, I., Tassone, B., Pujia, R., Ricchio, M., Serra, R., Sciacqua, A., Michael, A., Andreucci, M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.654557 · Cited by 34
Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice
Hudkins, K. L., Li, X., Holland, A. L., Swaminathan, S., & Alpers, C. E. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab330 · Cited by 34
van Baar, M. J. B., van der Aart, A. B., Hoogenberg, K., Joles, J. A., Heerspink, H. J. L., & van Raalte, D. H. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819865398 · Cited by 29
Self-citationAziri, B., Begić, E., Јаnkovic, S., Mladenović, Z., Stanetić, B., Kovačević-Preradović, T., Iglica, A., & Mujaković, A. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14355 · Cited by 33
Clinical Value of Complement Activation Biomarkers in Overt Diabetic Nephropathy
Pelletier, K., Bonnefoy, A., Chapdelaine, H., Pichette, V., Lejars, M., Madore, F., Brachemi, S., & Troyanov, S. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.03.004 · Cited by 31
Inaguma, D., Kitagawa, A., Yanagiya, R., Koseki, A., Iwamori, T., Kudo, M., & Yuzawa, Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239262 · Cited by 31
Cherney, D. Z. I., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Frederich, R. C., Maldonado, M., Liu, C., Pong, A., Cannon, C. P., et al. (2022) · American Journal of Nephrology · doi:10.1159/000524889 · Cited by 29
Self-citationThe New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
García-Carro, C., Vergara, A., Agraz, I., Jacobs-Cachá, C., Espinel, E., Serón, D., & Soler, M. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060864 · Cited by 29
“eGFR decreased in the empagliflozin group within the first weeks of treatment, but at the end of follow up, eGFR remained stable with empagliflozin compared to a decrease in the placebo group [30].”
BackgroundMethylation pattern of urinary DNA as a marker of kidney function decline in diabetes
Marumo, T., Hoshino, J., Kawarazaki, W., Nishimoto, M., Ayuzawa, N., Hirohama, D., Yamanouchi, M., Ubara, Y., Okaneya, T., Fujii, T., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001501 · Cited by 28
Sinha, F., Federlein, A., Biesold, A., Schwarzfischer, M., Krieger, K., Schweda, F., & Tauber, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1118358 · Cited by 27
“, 2019) and empagliflozin (Wanner et al., 2016; Wanner et al., 2018) in cardiovascular patients with type II diabetes.”
BackgroundCohen, C. M., Schechter, M., Rozenberg, A., Yanuv, I., Sehtman-Shachar, D. R., Fishkin, A., Rosenzweig, D., Chodick, G., Karasik, A., & Mosenzon, O. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000218 · Cited by 27
“Demographics Age, yr, mean (SD) 61 (11) 61 (12) Women, n (%) 3820 (39) 3868 (39) SES, n (%) 1–3 1227 (13) 1190 (12) 4–5 2911 (30) 2902 (30) 6–7 3442 (35) 3466 (35) 8–10 2229 (23) 2246 (23) Missing 15 (0.”
Safety and Tolerability of SGLT2 Inhibitors in Cardiac Amyloidosis—A Clinical Feasibility Study
Steinhardt, M., Cejka, V., Chen, M., Bäuerlein, S., Schäfer, J. M., Adrah, A., Ihne-Schubert, S. M., Papagianni, A. E., Kortüm, K. M., Morbach, C., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010283 · Cited by 27
“SGLT2i were reported to reduce the glomerular filtration pressure and thereby mitigate the long-term decline in the estimated glomerular filtration rate (eGFR) and albuminuria [12].”
BackgroundRuggenenti, P. L., Kraus, B. J., Inzucchi, S. E., Zinman, B., Hantel, S., Mattheus, M., von Eynatten, M., Remuzzi, G., Koitka‐Weber, A., & Wanner, C. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101240 · Cited by 25
Self-citationEmpagliflozin—A New Chance for Patients with Chronic Heart Failure
Kowalska, K., Walczak, J., Femlak, J., Młynarska, E., Franczyk, B., & Rysz, J. (2021) · Pharmaceuticals · doi:10.3390/ph15010047 · Cited by 24
“This results in a reduction in intraglomerular hypertension, diminishes glomerular hyperfiltration, attenuates albuminuria and thereby decelerates the progression of diabetic as well as non-diabetic chronic kidney disease (Figure 1) [34,35].”
BackgroundMalik, A. H., Yandrapalli, S., Goldberg, M. D., Jain, D., Frishman, W. H., & Aronow, W. S. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000265 · Cited by 23
Huang, J., Liu, Y., Shi, M., Zhang, X., Zhong, Y., Guo, S., Ma, Y., Pan, L., Yang, F., & Wang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117589 · Cited by 23
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors
O’Hara, D. V., & Jardine, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16385 · Cited by 22
“65,66 Despite early reports raising concern about an AKI risk with SGLT2 inhibitor use, 12 later clinical trial evidence 3 and large real-world studies 14,67 have demonstrated SGLT2 inhibitors reduce the risk of AKI.”
Lee, Y., Hsu, C., Fu, C.-M., Wang, S., Huang, C.-C., & Li, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.781379 · Cited by 22
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
“…BP through many other mechanisms including natriuresis, osmotic diuresis, reduced plasma volume, sodium pool, intraglomerular pressure and single nephron hy-perfiltration, improved endothelial function, arterial stiffness, glucose and serum urate levels, and reduced SNS activity [197 , 205 –207 ].”
Multimorbidity in Heart Failure: Leveraging Cluster Analysis to Guide Tailored Treatment Strategies
van de Veerdonk, M. C., Savarese, G., Handoko, M. L., Beulens, J. W. J., Asselbergs, F. W., & Uijl, A. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00626-w · Cited by 21
“Although an initial kidney function dip is expected, this initial change is reversible and not associated with adverse outcomes [51, 52].”
BackgroundTziastoudi, M., Pissas, G., Golfinopoulos, S., Filippidis, G., Dousdampanis, P., Eleftheriadis, T., & Stefanidis, I. (2023) · Life · doi:10.3390/life13122338 · Cited by 21
Zhou, F. L., Watada, H., Tajima, Y., Berthelot, M., Kang, D., Esnault, C., Shuto, Y., Maegawa, H., & Koya, D. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13753 · Cited by 21
Kohagura, K., Yamasaki, H., Takano, H., Ohya, Y., & Seino, Y. (2020) · Hypertension Research · doi:10.1038/s41440-020-0426-0 · Cited by 21
“Recent studies have shown that eGFR was maintained at stable levels over several years after an acute decline in eGFR, regardless of the basal eGFR levels [4, 30].”
BackgroundSabouret, P. F., Attias, D., Beauvais, C., Berthelot, E., Bouleti, C., Gibault‐Genty, G., Galat, A., Hanon, O., Hulot, J., Isnard, R., et al. (2021) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2021.05.004 · Cited by 21
KDIGO 2022 Clinical Practice Guideline For Diabetes Management in Chronic Kidney Disease
Статья, Р. (2023) · Nephrology and Dialysis · doi:10.28996/2618-9801-2023-2-141-221 · Cited by 21
Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome
Guerrero‐Mauvecin, J., Villar-Gómez, N., Miño-Izquierdo, L., Povo‐Retana, A., Ramos, A. M., Ruiz‐Hurtado, G., Sánchez-Niño, M. D., Ortíz, A., & Sanz, A. B. (2025) · Antioxidants · doi:10.3390/antiox14060701 · Cited by 20
“Both SGLT2i and GLP-1 RA reduce CVD and kidney outcomes by mechanisms beyond glycemic control [30,31].”
Girerd, N., & Zannad, F. M. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13620 · Cited by 20
Ngoc, N. B., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15201 · Cited by 19
Spiazzi, B. F., Piccoli, G. F., Wayerbacher, L. F., Lubianca, J. P. N., Scalco, B. G., Scheffler, M. H., Fraga, B. L., Colpani, V., & Gerchman, F. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000568 · Cited by 19
Bellos, I., Λάγιου, Π., Benetou, V., & Marinaki, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206181 · Cited by 19
“Growing evidence supports the renoprotective effects of SGLT2-i, as their administration has been linked to the long-term preservation of kidney function [53,54].”
The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
Liu, J., Tian, J., Sodhi, K., & Shapiro, J. I. (2021) · The Journal of Membrane Biology · doi:10.1007/s00232-021-00192-z · Cited by 19
Lorenzi, A. B. D., Kaplinsky, E., Zambrano, M. R., Chaume, L. T., & Rosas, J. M. (2023) · Drugs in Context · doi:10.7573/dic.2022-7-1 · Cited by 19
Cardiorenal interactions in heart failure: insights from recent therapeutic advances
Damman, K., & Testani, J. M. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad096 · Cited by 17
Role of Estimated Glomerular Filtration Rate in Clinical Research: The Never-Ending Matter
Abenavoli, C., Provenzano, M., Ksiazek, S. H., Hu, L., Cuna, V., Manna, G. L., Comai, G., & Baraldi, O. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2501001 · Cited by 17
Zaina, A., Grober, Y., Ali, A., Arad, E., Golden, E., & Badarny, S. (2021) · Endocrine · doi:10.1007/s12020-021-02718-w · Cited by 17
“This important class with a unique mode of action is widely used in type 2 diabetes mellitus (T2DM) and recently was approved for patients with heart failure with reduced ejection fraction and for patients with chronic kidney disease without diabetes [4, 5].”
BackgroundNakhleh, A., Abdul‐Ghani, M. A., Gazit, S., Gross, A., Livnat, I., Greenbloom, M., Yarden, A., Khazim, K., Shehadeh, N., & Cohen, C. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15623 · Cited by 16
“14 The slope of eGFR against time was calculated and analysed separately for each participant, during each period, using least squares regression.”
Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
Ramakrishnan, P., Garg, N., Pabich, S., Mandelbrot, D. A., & Swanson, K. J. (2023) · World Journal of Transplantation · doi:10.5500/wjt.v13.i5.239 · Cited by 16
“…PTDM prior to 12 mo; (2) major benefits of SGLT2i therapy such as eGFR preservation may require long term medication use, as EMPA-REG showed[35]; and (3) as is aptly described by Wolfe et al [41] in their seminal study on mortality after deceased donor kidney transplant (DDKT), there is…”
Sumida, Y., Yoneda, M., Toyoda, H., Yasuda, S., Tada, T., Hayashi, H., Nishigaki, Y., Suzuki, Y., Naiki, T., Morishita, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144939 · Cited by 16
Metadata
- Authors
- Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., Groop, P.-H., & on behalf of the EMPA-REG OUTCOME Investigators
- Affiliations
- Universitätsklinikum Würzburg (DE)
- University Medical Center Groningen (NL)
- Mount Sinai Hospital (CA)
- Yale University (US)
- Division of Nephrology, Department of Medicine, Würzburg University Clinic, Würzburg, Germany;
- Boehringer Ingelheim (Germany) (DE)
- Universität Ulm (DE)
- Boehringer Ingelheim International GmbH, Ingelheim, Germany;
- University of Helsinki (FI)
- Corresponding author
- Wanner, Christoph
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2018-10-12
- Volume
- 29
- Issue
- 11
- Pages
- 2755-2769
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- PMC
- PMC6218863
- OpenAlex
- W2897993744
- Cited by
- 209
- References
- 27
- Citations by year
- 2026: 15 · 2025: 12 · 2024: 22 · 2023: 35 · 2022: 38 · 2021: 31 · 2020: 29 · 2019: 25 · 2018: 1
- FWCI
- 17.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Lirias (KU Leuven) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- American Society of Nephrology
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- empagliflozin, renal function decline, type 2 diabetes, estimated glomerular filtration rate, eGFR slope, chronic kidney disease, EMPA-REG OUTCOME trial, SGLT2 inhibitors, drug discontinuation, renal function recovery, hemodynamic effects, cardiovascular risk reduction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glomerular Filtration Rate, Glucosides, Humans, Male, Middle Aged, Models, Statistical, Cohort Studies, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.